A drug’s active ingredient is the substance responsible for its activity.
More information about Active Substance
Substance,active substance,product,treatment,opinion,competent Authorities,body,forms,time,biocidal products,active ingredients,ingredients,human health,diagnosis,principles,biocidal active,authority,regulatory authorities,substance use disorders,drug substance,biological products,Commission,Commission Regulation,diseases,prevention of disease,assessments,review,inactive ingredients,active substance/product-type combination,dosage form,licenses,chemical,non-approval decision.
Application for approval,potential candidate,”220-120-9,Competent authority evaluation”,”222-720-6,Competent authority evaluation”,”225-208-0,Competent authority evaluation”,”233-539-7,Competent authority evaluation”,”-,222-720-6,Competent authority evaluation”,”201-501-9,244-445-0,Competent authority evaluation”,”214-619-0,Competent authority evaluation”,”219-768-5,Competent authority evaluation”,”233-539-7,225-208-0,Competent authority evaluation”,”238-588-8,Competent authority evaluation”,”244-445-0,Competent authority evaluation”,”401-400-1,Competent authority evaluation”,Competent Authority Meeting.
Competent authority report,active substance approval,active substance lists,active substance approval application,active substance generation combinations,active substance glyphosate,complete substance dossier,comprehensive substance,drug products,generic drug product,product candidates,Pesticide products,product performance,already-approved product,biologic product,”220-120-9,Commission decision”,European Commission,”233-539-7,Commission decision”,”262-104-4,Commission decision”.
Commission Implementing Regulation,infantile-onset Pompe disease,late-onset Pompe disease,disease community,disease in patients,disease mechanism,assessment period,diagnostic assessment,assessment phase,assessment report,comparative assessment,Review Programme Regulation,priority review pathway,joint review process,alignment in submission reviews,treatment of people,community treatment programs,comorbidity in treatment,Inert ingredients,positive opinion,”-222-8,Opinion development”,”229-222-8,Opinion development”,substance/product-type combinations,active substance/product-type centric,approved substance/product-type combinations,Health Canada,public health,animal health,body of evidence constituting,body of humans,nanomaterial forms,alternatives over time,application in time,accurate diagnosis,comorbid diagnosis,Biologic License Application,biologics license application,chemical entity,Chemical Types,active principle,basic principle.